

This is a repository copy of Cochrane systematic review and meta-analysis of the impact of psychological treatment on health-related quality of life in people with epilepsy: an update by the ILAE Psychology Task Force, highlighting methodological changes.

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/182342/

Version: Published Version

Article:

Michaelis, R., Tang, V., Nevitt, S.J. et al. (9 more authors) (2021) Cochrane systematic review and meta-analysis of the impact of psychological treatment on health-related quality of life in people with epilepsy: an update by the ILAE Psychology Task Force, highlighting methodological changes. Epileptic Disorders, 23 (6). pp. 803-811. ISSN 1294-9361

https://doi.org/10.1684/epd.2021.1357

Reuse

This article is distributed under the terms of the Creative Commons Attribution-ShareAlike (CC BY-SA) licence. This licence allows you to remix, tweak, and build upon the work even for commercial purposes, as long as you credit the authors and license your new creations under the identical terms. All new works based on this article must carry the same licence, so any derivatives will also allow commercial use. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Epileptic Disord 2021; 23 (6): 803-811



¹ Department of Neurology Gemeinschaftskrankenhaus Herdecke, University of Witten/ Herdecke, Herdecke, Germany ² Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, Bochum,

Germany ³ Division of Neurosurgery, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hospital Authority, Hong Kong ⁴ Department of Clinical Psychology, Prince of Wales Hospital, Hospital

Authority, Hong Kong ⁵ Department of Biostatistics, University of Liverpool, Liverpool, UK ⁶ College of Nursing, Medical University of South Carolina, Charleston, USA

 ²⁷ Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, USA
⁸ Departments of Psychiatry and Neurology, Rhode Island Hospital, Brown University, Providence, Rhode Island, USA

Rhode Island, USA ⁹ Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

¹⁰ Department of Psychology, Macquarie University, Sydney, Australia

 ¹¹ Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
¹² Department of Psychiatry, Clinics Hospital, Faculty of Medicine, University of São Paulo (HCFMUSP), Sao Paulo, Brazil
¹³ Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital and Neuroscience Institute, University of Cape Town, South Africa
¹⁴ Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK

Received April 16, 2021; Accepted May 26, 2021



Cochrane systematic review and meta-analysis of the impact of psychological treatment on health-related quality of life in people with epilepsy: an update by the ILAE Psychology Task Force, highlighting methodological changes^{*}

Rosa Michaelis^{1,2}, Venus Tang^{3,4}, Sarah J. Nevitt⁵, Janelle L. Wagner⁶, Avani C. Modi⁷, W. Curt LaFrance Jr⁸, Laura H. Goldstein⁹, Milena Gandy¹⁰, Rebecca Bresnahan¹¹, Kette Valente¹², Kirsten A. Donald¹³, Markus Reuber¹⁴

ABSTRACT

Clinical interest in using psychological interventions for people with epilepsy (PWE) aiming at decreasing mental health difficulties, improving health-related quality of life (HRQOL) and seizure-related outcomes, continues to grow. This article summarizes the 2020 update of the 2017 Cochrane Review and meta-analysis of psychological interventions for PWE, highlighting the reasons for major methodological modifications such as the recategorization of interventions and expanded risk of bias assessment. A 2020 literature search yielded 36 RCTs (n=3526) investigating psychological treatments for PWE with a validated HRQOL measure as an outcome. Twenty-seven trials were skills-based psychological interventions, 11 studies (n=643) used the Quality of Life in Epilepsy-31 (QOLIE-31) or other QOLIE inventories convertible to QOLIE-31 as an outcome measure and were pooled for meta-analysis. Significant mean changes were observed for the QOLIE-31 total score (mean improvement of 5.23 points; p< 0.001) and in six out of seven subscales (emotional well-being, energy and fatigue,

* This article is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews (CDSR) 2020, Issue 8: CD012081. DOI: 10.1002/14651858.CD012081.pub3 (see www.cochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the CDSR should be consulted for the most recent version of the review.

• Correspondence:

Rosa Michaelis Department of Neurology Gemeinschaftskrankenhaus Herdecke, University of Witten/Herdecke, Herdecke, Germany

<rosa.michaelis@uni-wh.de>, <rosa.michaelis@kk-bochum. de>, <rosamichaelis@posteo.de> overall QoL, seizure worry, medication and cognitive functioning). The mean changes in the QOLIE-31 total score and the overall QoL subscale exceeded the threshold of minimally important change (MIC), indicating clinically meaningful post-intervention improvement. These results provide moderate evidence that psychological treatments for adults and adolescents with epilepsy enhance HRQOL. In addition to the summary of the Cochrane review, we provide a detailed characterization of the interventions and patient populations of the meta-analyzed studies.

Key words: mental health, nonadherence, psychoeducation, self-management, psychological interventions

Given the significant impact that epilepsy may have on the health-related quality of life (HRQOL) of individuals with epilepsy and their families, there is increasing interest in evidence-based psychological treatments, aimed at enhancing mental health and seizure-related outcomes for this group. This is a summary of the 2020 update [1] of the 2017 Cochrane Review [2] of controlled studies of psychological treatments in people with epilepsy (PWE). The objective was to assess the impact of psychological treatments on HRQOL outcomes in PWE. The update included major methodological modifications and the latest results.

Methods

Search methods

In this update, we searched the following databases on 12 August 2019, without language restrictions: Cochrane Register of Studies (CRS Web), which includes randomized or quasi-randomized controlled trials from the Specialized Registers of Cochrane Review Groups including Epilepsy, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid, 1946 to 09 August 2019), and PsycINFO (EBSCOhost, 1887 onwards), and PubMed, Embase, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (ICTRP). In addition, we screened the references from included studies and relevant reviews.

Selection criteria

We considered randomized controlled trials (RCTs) and quasi-RCTs that investigated psychological treatments for people with epilepsy using HRQOL as a primary or secondary outcome measure. We included a broad range of psychological treatments designed to improve HRQOL, seizure frequency or severity, as well as mental health comorbidities for adults and children with epilepsy. These psychological treatments were variously compared to treatment as usual (TAU, which most commonly included follow up with neurologists or epileptologists for pharmacological treatment of seizures), an active control group (e.g., a social support group with equivalent contact hours), or antidepressant pharmacotherapy (in studies that included patients with epilepsy and comorbid mood disorder).

Re-categorization of psychological interventions

While the previous review had grouped psychological interventions in five groups: psychological interventions, self-management/family management, adherence, (psycho-) educational and mixed interventions, these were collapsed into two categories in this updated Cochrane review: (1) education-only interventions and (2) skills-based psychological interventions. The new operational categorization emphasized commonalities of the interventions' components rather than differences, and was intended to increase comprehensibility. Education-only interventions were defined as those that provide epilepsy-related facts and knowledge, while skills-based psychological interventions (which may involve educational elements) require an engaged learner who acquires and applies skills and knowledge to achieve psychological and behavioral changes.

Data collection and analysis

We used the standard methodological procedures required by Cochrane [3].

Results

The 2017 Cochrane review included 24 completed RCTs (2,439 participants); this updated review included 36 completed RCTs, with a total of 3,526 participants. The 50% growth in trials in just two years

demonstrated the growing interest in the investigation of psychological interventions for people with epilepsy. Of these studies, 27 investigated skills-based psychological interventions [4-30]. The remaining nine studies were education-only interventions [31-39]. Five studies investigated interventions for children and adolescents [24, 30, 35, 36, 39], six for adolescents and adults [12, 20, 29, 31, 32, 34], and the remaining studies for adults only.

Expanded risk of bias assessment in studies of psychological interventions

Due to an increased interest in risk of bias domains in evaluating psychological interventions [40], we considered three additional potential sources of bias in this updated review, including (1) fidelity to the intervention protocol, (2) competence in treatment delivery, and (3) selective recruitment. We contacted authors to gather this additional information.

Features of therapeutic interactions may vary from therapist to therapist, and this may be an inherent characteristic in psychological interventions. Efforts in measuring fidelity to psychological intervention protocols and competence in treatment delivery have been increasingly recognized in recent years [40].

In our included studies, little information was provided to judge risk of bias in terms of fidelity to the intervention protocol. Six studies reported the use of measures to assess fidelity. While two recent studies reported the actual results of their analysis [27, 32], results of the described fidelity assessment of one of the older studies was provided by the authors upon our request [28]. Moreover, three additional studies disclosed details on their procedures to assess fidelity to the intervention protocol [22, 24, 33]. We rated risk of poor fidelity to treatment protocol as 'low' in all of these studies. We also considered the risk of poor fidelity to the intervention protocol as 'low' in three studies in which the delivery of the intervention was internet-based [10, 26, 41]. All remaining studies were rated as 'unclear', in terms of risk of poor fidelity to intervention protocol.

Two dimensions of competence in treatment delivery were assessed. First, we reviewed the competence in terms of the professional training background of personnel who delivered the intervention. Second, we reviewed the competence of the measures used to assess the quality of actual treatment delivery. In internet-based intervention programs, we only evaluated the training background of the professionals who had designed the intervention. Most studies reported the training background of personnel delivering the intervention, and risk of bias was therefore rated 'low' in these studies (n = 28 studies). In terms of the quality of actual delivery as a component of competence, four studies reported the use of measures to assess competence and these results were reported in three studies [7, 28, 32]. Three authors provided additional details about their attempts to assess competence with reported results [9, 16, 17]. Consequently, we judged the risk of poor competence to be 'low' in all six studies and to be 'unclear' for the remaining studies. Risk of selective recruitment was considered 'low' in all 13 studies that reported consecutive recruitment at the intervention site including screening of all patients for eligibility [5, 7, 9, 13, 18, 20, 24, 27-29, 32-34]. Risk of selective recruitment was considered 'high' in all studies in which the recruitment procedure involved subjective criteria (n = 2: [4, 22]), advertisements (n = 9: [8, 10, 15-17, 21, 26, 31, 35]) or convenience sampling (n = 1; [6]). Recruitment procedures were 'unclear' in all remaining studies.

The risk of bias assessment of all domains is shown in *supplementary figure 1*. Limited ability to blind participants and personnel in trials investigating psychological interventions continued to be the area for which the risk of bias is highest. Implications for psychotherapy research are discussed below in future directions.

The reception of psychological interventions depends on participants' motivation to actively engage in the intervention, and attrition across the intervention and follow-up period also continued to be high in more recent trials (see *supplementary figure 1*).

Characteristics of interventions, designs, and participants included in meta-analysis

Based on satisfactory clinical and methodological homogeneity among the skills-based interventions, we pooled data from 11 studies (643 participants) that used the Quality of Life in Epilepsy-31 (QOLIE-31) or other QOLIE inventories (such as QOLIE-89 or QOLIE-31-P) convertible to QOLIE-31 [4, 8, 9, 11, 12, 14, 18, 20-22, 29]. The control groups comprised treatment as usual (n = 5), waiting-list control (n = 2), antidepressant pharmacotherapy (n = 2), supportive therapy (n = 1), and an alternative psychological intervention (n = 1).

The skills-based interventions that were included in meta-analysis comprised five trials with a main treatment goal of reducing depressive symptoms [8, 9, 11, 12, 14], two self-management interventions [21, 22], two mixed interventions (self-management and memory training, psychoeducation and counseling) [20, 29], one mindfulness-based intervention with a main treatment goal of improving HRQOL [18], and one cognitive-behavioral therapy intervention primarily aimed at reducing seizures [4]. The median duration of the interventions included in the meta-analysis was eight weeks (range: 8 weeks-2 years). The median number of sessions was eight (range: 5-20) on a weekly (n = 8), biweekly (n = 2), or an irregular (n = 1) basis. Three interventions included a median of four monthly booster sessions (range: 1 - 9) following the more frequent treatment period [12, 14, 22].

The majority of interventions were delivered in a group format (n = 6 = [4, 11, 12, 18, 21, 22]. In the remaining five trials, interventions were delivered in an individual format; two of these trials included an initial psychoeducation session in a group format [20, 29]. Individual sessions lasted between 50 minutes and one hour, while group sessions lasted between one hour and 2.5 hours. The duration of sessions was unknown in two trials [12, 20]. The interventions were delivered by psychologists (n = 6), epilepsy nurses (n = 6)4), social workers (n = 2), licensed therapists (n = 1), and a psychiatrist (n = 1). Two group interventions were delivered by interprofessional teams [11, 12] and two involved peer mentors [21, 22]. Intervention delivery in five trials had been manualized [8, 12, 14, 21, 29]; in two of these trials, interventionists (social workers, nurses) had received two days of training prior to the delivery of the intervention manuals [14, 29] (see table 1). Two of the 11 meta-analyzed studies included adolescents only [12] or adults and adolescents [29], respectively. All other studies included only adults; none of the studies in the meta-analysis included children. The exact percentage of all study participants (n=675) who had drug-resistant epilepsy and depression could not be calculated based on the information provided, e.g. some trials did not capture whether patients had a depressive episode at baseline. However, at least 53% (353 participants) were not seizure-free and at least 35% (234 participants) were likely to be clinically depressed based on a structured clinical interview (98 participants), scores on selfreport questionnaires (94 participants) or prescription of antidepressants (42 participants) at the time of recruitment.

Meta-analysis

As in the previous review, we found significant mean changes in the QOLIE-31 total score and in six out of seven subscales (emotional well-being, energy and fatigue, overall QoL, seizure worry, medication effects, and cognitive functioning). The mean changes in the QOLIE-31 total score (mean improvement of 5.23 points, 95% CI: 3.02 to 7.44; p < 0.001), and the overall QoL score (mean improvement of 5.95 points, 95% CI: 3.05 to 8.85; p < 0.001) exceeded the threshold of minimally important change (MIC: QOLIE-31 total score: 4.73 points; overall QoL score: 5.22 points), indicating a clinically meaningful post-intervention improvement in HRQOL (see figures 1A, B) [42].

In the previous Cochrane review [2], the total score and three subscales (emotional well-being, energy and fatigue, and overall QOL) had exceeded the minimally important change (MIC) threshold. However, in this update, we downgraded the certainty of the evidence provided by the initial meta-analysis due to serious risks of bias uncovered in some of the included studies (see *supplementary figure 1*). Consequently, these results are now judged to provide evidence of moderate certainty that psychological treatments for adults with epilepsy may enhance overall HRQOL.

Conclusions

Implications for clinical practice

Skills-based psychological interventions improve HRQOL in adults and adolescents with epilepsy. Adjunctive use of skills-based psychological treatments for adults and adolescents with epilepsy may provide additional benefits in HRQOL when incorporated into patient-centered epilepsy management. We judge the existing evidence to be of moderate certainty. Practical conclusions for education-only interventions have previously been formulated in a separate evidence-based recommendation paper by the ILAE Psychology Task Force [43]. The use of psychological interventions is another resource in the armamentarium for management of PWE.

Implications for research design and reporting

Based on the 2017 Cochrane review [2], recommendations for the implementation of psychological clinical trials in epilepsy have been formulated [44]. Investigators are encouraged to strictly adhere to the CONSORT guidelines in order to improve the quality of reporting of their psychological interventions. A thorough description of intervention protocols is necessary to ensure reproducibility. When examining the effectiveness of psychological treatments for people with epilepsy, the use of standardized HRQOL inventories, such as the Quality of Life in Epilepsy Inventories (QOLIE-31, QOLIE-31-P, and QOLIE-89) would increase comparability. In order to increase the overall quality of RCT study designs, adequate randomization with allocation concealment and blinded outcome assessment should be pursued, where feasible. As attrition is often high in clinical trials that require active participation, an intention-totreat analysis should be carried out. In order for RCTs in this area to inform clinical practice with greater confidence, attention should be paid to the assessment of treatment fidelity and treatment competence. Lastly, given that a clinician cannot be blinded to what

	Study (Intervention)	Therapist(s)	Main Goal	Intervention duration	Delivery method/ Number of sessions	Control group
	Ciechanowski et al. 2010 [14] (PEARLS)	3 master-level social workers	↓ Depressive symptoms	12 months	Individual / 8 biweekly 50-min sessions + 8 monthly 5-10-min phone calls	TAU
Cognitive behavioral therapy	Gandy <i>et al.</i> 2014 [8]	1 intern psychologist	↓ Depressive symptoms	8 weeks	Individual /8 weekly 1-hr sessions	WLC
	Gilliam <i>et al.</i> 2019 [9]	1 social worker (accreditation in therapy >10 years), 2 PhD-level psychologists	↓ Depressive symptoms	16 weeks	Individual /16 weekly 1-hr sessions	SSRI
(CBT)	Martinovic et al. 2006 [12]	1 psychlogist, 1 epilepsy nurse	↓ Depressive symptoms	6 months	Group / 8 weekly sessions + 4 monthly sessions	TAU
	Orjuela-Rojas <i>et al</i> . 2015 [11]	1 licensed therapist in CBT, 1 psychiatrist	↓ Depressive symptoms	12 weeks	Group / 12 weekly 90-min sessions	SSRI
	Au <i>et al</i> . 2003 [4]	2 clinical psychologist	↓ Seizure frequency	8 weeks	Group /2-hr sessions for 8 weeks	WLC
Self-	Fraser <i>et al.</i> 2015 [21] (PACES)	2 PhD-level rehabilitation psychologists, 1 peer mentor w/ epilepsy	↑ Self- management	8 weeks	Group / 8 weekly 75-min sessions	TAU
management	Leenen <i>et al.</i> 2018 [22] (ZMILE)	1 nurse educator, 1 peer educator w/ epilepsy	↑ Self- management and ↑ HRQoL	8 weeks	Group /5 weekly 1-hr session + 1-hr booster session	TAU
Mindfulness- based therapy	Tang <i>et al</i> . 2015 [18]	1 clinical psychologist with 5 years of clinical experience	↑ HRQoL	8 weeks	Group /4 biweekly 2.5-hr sessions	Supportive therapy
Self-mgt + memory training	Caller <i>et al.</i> 2016 [29] (HOBSCOTCH)	1 epilepsy specialized ARNP, 1 RN trained as "memory coach"	↑ HRQoL	8 weeks	Group and individual / 8 weekly 45-60-min sessions	TAU
Education + counselling	Helde <i>et al.</i> 2005 [20]	1 nurse with > 15yrs of clinical experience with epilepsy	↑ HRQoL	2 years	Group and individual /1-day education + 20 phone sessions	TAU

Table 1. Characteristics of interventions and participants included in the meta-analysis.

ARNP: Advanced Registered Nurse Practitioner; HOBSCOTCH; Home Based Self-management and Cognitive Training Changes Lives; HRQoL: Health Related Quality of Life; PEARLS: Program to Encourage Active Rewarding Lives; RN: registered nurse; SSRI: selective serotonin reuptake inhibitor; TAU: treatment as usual; WLC: waiting list control; w/: with; yrs: years.

	psych	nologic	al tx	U	C or SC	2		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Au 2003	10.42	6.58	8	-0.9	8.18	9	7.0%	11.32 [4.30, 18.34]	
Caller 2016	4.7	10.3	29	-1.9	12.7	20	7.5%	6.60 [-0.11, 13.31]	
Ciechanowski 2010	5.73	14.36	32	1.33	10.64	33	8.4%	4.40 [-1.76, 11.25]	
raser 2015	5.82	9.61	38	-1.29	9.02	40	13.0%	7.11 [2.97, 11.25]	
Gandy 2014	3.92	11.3	20	0.33	8.58	25	8.7%	3.59 [-2.40, 9.58]	
Gilliam 2019	15.67	19.9	55	15.96	15.08	56	7.7%	-0.29 [-6.87, 6.29]	
Helde 2005	3.27	11.53	56	2.63	12.06	53	12.2%	0.64 [-3.79, 5.07]	
eenen 2018	6.39	9.47	31	0.36	7.5	33	12.8%	6.03 [1.83, 10.23]	
Aartinovic 2006	15.83	11.8	15	2.87	7.53	15	6.9%	12.96 [5.88, 20.04]	
Orjuela-Rojas 2015	17.25	20.58	7	8.14	11.26	8	1.6%	9.11 [-8.02, 26.24]	
Fang 2015	7.29	7.06	30	3.97	7.33	30	14.5%	3.32 [-0.32, 6.96]	
						222	100.00/		
Fotal (95% CI)			321			322	100.0%	5.23 [3.02, 7.44]	
Fotal (95% CI) Heterogeneity: Tau ²	= 5.32; 0	Chi ² = 1		f = 10 (P = 0.08			5.23 [3.02, 7.44]	\
			6.89, d		P = 0.08			5.23 [3.02, 7.44]	
Heterogeneity: Tau ² Test for overall effec	rt: Z = 4.0	64 (P <	6.89, d 0.00001)		B); $ ^2 = 4$			Favours UC or SC Favours psychological tx
Heterogeneity: Tau ²	rt: Z = 4.0	64 (P < nologic	6.89, d 0.00001 al tx) U	C or SC	B); $ ^2 = 4$		Mean Difference	
Heterogeneity: Tau ² Test for overall effec	rt: Z = 4.0	64 (P < nologic	6.89, d 0.00001 al tx)	C or SC	3); l ² = 4	41%		Favours UC or SC Favours psychological tx
Heterogeneity: Tau ² Fest for overall effect Study or Subgroup	t: Z = 4.0 psych	64 (P < nologic	6.89, d 0.00001 al tx) U	C or SC	3); l ² = 4	41%	Mean Difference	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Fest for overall effect Study or Subgroup Au 2003	t: Z = 4.0 psych <u>Mean</u>	64 (P < nologic SD	6.89, d 0.00001 al tx Total) U(<u>Mean</u>	C or SC SD	3); l ² = 4 C Total	41% Weight	Mean Difference IV, Random, 95% CI	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Fest for overall effect Study or Subgroup Au 2003 Caller 2016	t: Z = 4.0 psych <u>Mean</u> 14.07 2.2	64 (P < nologic <u>SD</u> 11.7	6.89, d 0.00001 al tx <u>Total</u> 8) U(<u>Mean</u> -1.39	C or SC SD 9.75	3); ² = 4 <u>5</u> <u>Total</u> 9	41% <u>Weight</u> 6.2%	Mean Difference IV, Random, 95% Cl 15.46 [5.15, 25.77]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Fest for overall effect Study or Subgroup Au 2003 Caller 2016 Ciechanowski 2010	t: Z = 4.0 psych <u>Mean</u> 14.07 2.2 5.62	64 (P < nologic <u>SD</u> 11.7 11.9	6.89, d 0.00001 al tx <u>Total</u> 8 29) U(<u>Mean</u> -1.39 -6	C or SC SD 9.75 16.9 12	$\frac{1}{2} = \frac{1}{2}$	41% Weight 6.2% 8.2%	Mean Difference IV, Random, 95% CI 15.46 [5.15, 25.77] 8.20 [0.38, 16.78]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Fest for overall effect Study or Subgroup Au 2003 Caller 2016 Ciechanowski 2010 Fraser 2015	t: Z = 4.0 psych <u>Mean</u> 14.07 2.2 5.62 7.43	64 (P < nologic <u>SD</u> 11.7 11.9 21.22	6.89, d 0.00001 al tx <u>Total</u> 8 29 32) U(<u>Mean</u> -1.39 -6 2	C or SC SD 9.75 16.9 12	$\frac{1}{20}; ^2 = \frac{1}{20}$	41% Weight 6.2% 8.2% 8.4%	Mean Difference IV, Random, 95% CI 15.46 [5.15, 25.77] 8.20 [0.38, 16.78] 3.62 [-4.80, 12.04]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Test for overall effect tudy or Subgroup Au 2003 Caller 2016 Ciechanowski 2010 Traser 2015 Gandy 2014	t: Z = 4.0 psych <u>Mean</u> 14.07 2.2 5.62 7.43	64 (P < nologic <u>SD</u> 11.7 11.9 21.22 15.56	6.89, d 0.00001 al tx <u>Total</u> 8 29 32 38	U Mean -1.39 -6 2 -2.63	C or SC <u>SD</u> 9.75 16.9 12 13.64	3); $ ^2 = 4$ Total 9 20 33 40	41% Weight 6.2% 8.2% 8.4% 11.7%	Mean Difference IV, Random, 95% CI 15.46 [5.15, 25.77] 8.20 [0.38, 16.78] 3.62 [-4.80, 12.04] 10.06 [3.55, 16.57]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Test for overall effect Study or Subgroup Au 2003 Caller 2016 Ciechanowski 2010 Fraser 2015 Gandy 2014 Gilliam 2019	tt: Z = 4.0 psych Mean 14.07 2.2 5.62 7.43 0.13 17.97	64 (P < nologic <u>SD</u> 11.7 11.9 21.22 15.56 13.49	6.89, d 0.00001 al tx <u>Total</u> 8 29 32 38 20) <u>Mean</u> -1.39 -6 2 -2.63 -0.78 15	C or SC SD 9.75 16.9 12 13.64 11.3	3); ² = - Total 9 20 33 40 25	41% Weight 6.2% 8.2% 8.4% 11.7% 10.0%	Mean Difference IV, Random, 95% CI 15.46 [5.15, 25.77] 8.20 [0.38, 16.78] 3.62 [-4.80, 12.04] 10.06 [3.55, 16.57] 0.91 [-6.48, 8.30]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Test for overall effect Study or Subgroup Au 2003 Caller 2016 Ciechanowski 2010 Graser 2015 Gandy 2014 Cilliam 2019 Helde 2005	tt: Z = 4.0 psych <u>Mean</u> 14.07 2.2 5.62 7.43 0.13 17.97 3.29	64 (P < nologic SD 11.7 11.9 21.22 15.56 13.49 23.5	6.89, d 0.00001 al tx <u>Total</u> 8 29 32 38 20 58) <u>Mean</u> -1.39 -6 2 -2.63 -0.78 15 4.09	C or SC SD 9.75 16.9 12 13.64 11.3 18.16	3); ² = - Total 9 20 33 40 25 59	41% Weight 6.2% 8.2% 8.4% 11.7% 10.0% 9.6%	Mean Difference IV, Random, 95% Cl 15.46 [5.15, 25.77] 8.20 [0.38, 16.78] 3.62 [-4.80, 12.04] 10.06 [3.55, 16.57] 0.91 [-6.48, 8.30] 2.97 [-4.65, 10.59]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Test for overall effect Study or Subgroup Au 2003 Caller 2016 Ciechanowski 2010 Traser 2015 Gandy 2014 Gilliam 2019 Helde 2005 Leenen 2018	t: Z = 4.0 psych Mean 14.07 2.2 5.62 7.43 0.13 17.97 3.29 3.29	64 (P < 1000 cm	6.89, d 0.00001 al tx <u>Total</u> 8 29 32 38 20 58 57) <u>Mean</u> -1.39 -6 2 -2.63 -0.78 15 4.09 -2.6	C or SC SD 9.75 16.9 12 13.64 11.3 18.16 16.34	3); ² = - Total 9 20 33 40 25 59 54	41% Weight 6.2% 8.2% 8.4% 11.7% 10.0% 9.6% 12.3%	Mean Difference IV, Random, 95% CI 15.46 [5.15, 25.77] 8.20 [0.38, 16.78] 3.62 [-4.80, 12.04] 10.06 [3.55, 16.57] 0.91 [-6.48, 8.30] 2.97 [-4.65, 10.59] -0.80 [-7.07, 5.47]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Fest for overall effec	tt: Z = 4.0 psych Mean 14.07 2.2 5.62 7.43 0.13 17.97 3.29 3.29 19.64	64 (P < 64 (P	6.89, d 0.00001 al tx <u>Total</u> 8 29 32 38 20 58 57 41) <u>Mean</u> -1.39 -6 2 -2.63 -0.78 15 4.09 -2.6	C or SC SD 9.75 16.9 12 13.64 11.3 18.16 16.34 12.12	B); ² = - Total 9 20 33 40 25 59 54 41	41% Weight 6.2% 8.2% 8.4% 11.7% 10.0% 9.6% 12.3% 14.5%	Mean Difference IV, Random, 95% CI 15.46 [5.15, 25.77] 8.20 [0.38, 16.78] 3.62 [-4.80, 12.04] 10.06 [3.55, 16.57] 0.91 [-6.48, 8.30] 2.97 [-4.65, 10.59] -0.80 [-7.07, 5.47] 5.89 [0.53, 11.25]	Favours UC or SC Favours psychological tx Mean Difference
Heterogeneity: Tau ² Test for overall effect Study or Subgroup Au 2003 Caller 2016 Ciechanowski 2010 Traser 2015 Gandy 2014 Gilliam 2019 Helde 2005 Leenen 2018 Drjuela-Rojas 2015	tt: Z = 4.0 psych Mean 14.07 2.2 5.62 7.43 0.13 17.97 3.29 3.29 19.64	64 (P < 6 nologic SD 11.7 11.9 21.22 15.56 13.49 23.5 17.37 12.62 16.29	6.89, d 0.00001 al tx Total 8 29 32 38 20 58 57 41 7) <u>Mean</u> -1.39 -6 2 -2.63 -0.78 15 4.09 -2.6 2.82	C or SC SD 9.75 16.9 12 13.64 11.3 18.16 16.34 12.12 18.44	$\begin{array}{l} \text{(3)}; \ ^2 = - \\ \hline \\ \textbf{Total} \\ 9 \\ 20 \\ 33 \\ 40 \\ 25 \\ 59 \\ 54 \\ 41 \\ 8 \\ 30 \end{array}$	41% Weight 6.2% 8.2% 8.4% 11.7% 9.6% 12.3% 14.5% 2.5%	Mean Difference IV, Random, 95% Cl 15.46 [5.15, 25.77] 8.20 [0.38, 16.78] 3.62 [-4.80, 12.04] 10.06 [3.55, 16.57] 0.91 [-6.48, 8.30] 2.97 [-4.65, 10.59] -0.80 [-7.07, 5.47] 5.89 [0.53, 11.25] 16.82 [-0.76, 34.40]	Favours UC or SC Favours psychological tx Mean Difference

Figure 1. Forest plots of comparisons with mean change from baseline of (A) Quality of Life in Epilepsy (QOLIE)-31 total score, and (B) overall Quality of Life (QoL) subscale score.Sample size information can be found in the columns labeled "Total." Effect sizes are stated in the columns labeled "Mean Difference". CI: confidence interval; IV: inverse variance; SC: Social Care; SD: standard deviation; tx: therapy; UC: Usual Care.

type of therapy they are giving, and that a patient/ participant will also know that they are receiving a particular therapy, conducting a "double-blind" psychotherapy trial is not possible. In light of that design impossibility for psychotherapy trials, the risk bias rating for the intervention masking could be mitigated by including outcome raters who are blinded to which arm the participant is enrolled. Future high-quality studies of psychological interventions for PWE may provide support for these and other interventions.

Depression has a strong association with HRQOL in epilepsy, and psychological interventions (particularly cognitive behavioral therapy) are recognized as effective therapies for depression. Hence, future studies of psychological interventions should include a sub-analysis of patients with major depression and delineate to what extent improvements in HRQOL in epilepsy are mediated by the reduction of depressive symptoms.

Identified gaps and future directions

With increasing evidence that psychological treatments benefit adults and adolescents with PWE, there has been much discussion on resource allocation informed by the identification of care priorities. Participants in our included studies were heterogeneous regarding seizure control, drug responsiveness and psychiatric comorbidities. Some studies did not include these characteristics as criteria for patient selection, while some delivered psychological treatment to a specific group of patients with epilepsy (e.g. drug-resistant epilepsy, epilepsy and comorbid depression). We recommend that psychological treatments be incorporated as part of standard comprehensive care for PWE. However, with a reasonable concern for limited resources, future studies with subgroup analyses (e.g. drug-resistant epilepsy, epilepsy with distinct comorbid psychiatric

disorders) and health economic outcome measures (e. g. direct and indirect health care costs; common metrics used in cost-effectiveness analyses: cost per quality-adjusted life year [QALY] gained and cost per disability-adjusted life year [DALY]) may provide further insights into optimal resource allocation.

Of note, only a small number of RCTs were conducted on pediatric populations. A similar gap has been identified in trials on PWE and comorbid intellectual disabilities, including special training for their caregivers. Further development on psychological treatment protocols specifically for these populations is needed.

Supplementary material.

Supplementary figure and summary slides accompanying the manuscript are available at www.epilepticdisorders.com.

Acknowledgements and disclosures.

RM received funding from the internal grant program (project IFF 2020-28) of the Faculty of Health at Witten/Herdecke University, Germany. MG is supported by a Macquarie University Research Fellowship. This paper describes independent research, partly funded (LHG) by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King's College London. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. KV received funding from the National Council for Scientific and Technological Development (307817/2019-9)

This report was written by experts selected by the International League Against Epilepsy and was approved for publication by the ILAE. Opinions expressed by the authors, however, do not necessarily represent the policy or position of the ILAE. The authors report no disclosures. This publication represents work of the ILAE Psychology Task Force members. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References

1. Michaelis R, Tang V, Nevitt SJ, Wagner JL, Modi AC, LaFrance Jr W, *et al.* Psychological treatments for people with epilepsy. *Cochrane Database of Syst Rev* 2017; 2017(10): CD012081.

2. Michaelis R, Tang V, Wagner JL, Modi AC, Curt LaFrance Jr W, Goldstein LH, *et al*. Cochrane systematic review and metaanalysis of the impact of psychological treatments for people with epilepsy on health-related quality of life. *Epilepsia* 2018; 59: 315-32.

3. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions version 6.1. Cochrane, 2020.

4. Au A, Chan F, Li K, Leung P, Li P, Chan J. Cognitivebehavioral group treatment program for adults with epilepsy in Hong Kong. *Epilepsy Behav* 2003; 4: 441-6.

5. Ring H, Howlett J, Pennington M, Smith C, Redley M, Murphy C, *et al.* Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT. *Health Technol Assess* 2018; 22: 1-104.

6. Hosseini N, Mokhtari S, Momeni E, Vossoughi M, Barekatian M. Effect of motivational interviewing on quality of life in patients with epilepsy. *Epilepsy Behav* 2016; 55: 70-4.

7. Pakpour AH, Gholami M, Esmaeili R, Naghibi SA, Updegraff JA, Molloy GJ, *et al.* A randomized controlled multimodal behavioral intervention trial for improving antiepileptic drug adherence. *Epilepsy Behav* 2015; 52: 133-42.

8. Gandy M, Sharpe L, Nicholson Perry K, Thayer Z, Miller L, Boserio J, *et al.* Cognitive behaviour therapy to improve mood in people with epilepsy: a randomised controlled trial. *Cogn Behav Ther* 2014; 43: 153-66.

9. Gilliam FG, Black KJ, Carter J, Freedland KE, Sheline YI, Tsai WY, *et al.* A trial of sertraline or cognitive behavior therapy for depression in epilepsy. *Ann Neurol* 2019; 86: 552-60.

10. Meyer B, Weiss M, Holtkamp M, Arnold S, Bruckner K, Schroder J, *et al.* Effects of an epilepsy-specific Internet intervention (Emyna) on depression: Results of the ENCODE randomized controlled trial. *Epilepsia* 2019; 60: 656-68.

11. Orjuela-Rojas JM, Martinez-Juarez IE, Ruiz-Chow A, Crail-Melendez D. Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy *vs.* selective serotonin reuptake inhibitors. *Epilepsy Behav* 2015; 51: 176-81.

12. Martinović Z, Simonović P, Djokić R. Preventing depression in adolescents with epilepsy. *Epilepsy Behav* 2006; 9: 619-24.

13. Thompson NJ, Walker ER, Obolensky N, Winning A, Barmon C, Diiorio C, *et al.* Distance delivery of mindfulnessbased cognitive therapy for depression: project UPLIFT. *Epilepsy Behav* 2010; 19: 247-54.

14. Ciechanowski P, Chaytor N, Miller J, Fraser R, Russo J, Unutzer J, *et al.* PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. *Epilepsy Behav* 2010; 19: 225-31.

15. Schröder J, Brückner K, Fischer A, Lindenau M, Köther U, Vettorazzi E, *et al.* Efficacy of a psychological online intervention for depression in people with epilepsy: a randomized controlled trial. *Epilepsia* 2014; 55: 2069-76.

16. Lundgren T, Dahl J, Melin L, Kies B. Evaluation of acceptance and commitment therapy for drug refractory epilepsy: a randomized controlled trial in South Africa–a pilot study. *Epilepsia* 2006; 47: 2173-9.

17. Lundgren T, Dahl J, Yardi N, Melin L. Acceptance and commitment therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. *Epilepsy Behav* 2008; 13: 102-8.

18. Tang V, Poon WS, Kwan P. Mindfulness-based therapy for drug-resistant epilepsy: an assessor-blinded randomized trial. *Neurology* 2015; 85: 1100-7.

19. Hum KM, Chan CJ, Gane J, Conway L, McAndrews MP, Smith ML. Do distance-delivery group interventions improve depression in people with epilepsy? *Epilepsy Behav* 2019; 98: 153-60.

20. Helde G, Bovim G, Bråthen G, Brodtkorb E. A structured, nurse-led intervention program improves quality of life in patients with epilepsy: a randomized, controlled trial. *Epilepsy Behav* 2005; 7: 451-7.

21. Fraser RT, Johnson EK, Lashley S, Barber J, Chaytor N, Miller JW, *et al.* PACES in epilepsy: results of a self-management randomized controlled trial. *Epilepsia* 2015; 56: 1264-74.

22. Leenen LAM, Wijnen BFM, Kessels AGH, Chan H, de Kinderen RJA, Evers S, *et al.* Effectiveness of a multicomponent self-management intervention for adults with epilepsy (ZMILE study): a randomized controlled trial. *Epilepsy Behav* 2018; 80: 259-65.

23. Pramuka M, Hendrickson R, Zinski A, Van Cott AC. A psychosocial self-management program for epilepsy: a randomized pilot study in adults. *Epilepsy Behav* 2007; 11: 533-45.

24. Dorris L, Broome H, Wilson M, Grant C, Young D, Baker G, *et al*. A randomized controlled trial of a manual-based psychosocial group intervention for young people with epilepsy [PIE]. *Epilepsy Behav* 2017; 72: 89-98.

25. Yadegary MA, Maemodan FG, Nayeri ND, Ghanjekhanlo A. The effect of self-management training on health-related quality of life in patients with epilepsy. *Epilepsy Behav* 2015; 50: 108-12.

26. Dilorio C, Bamps Y, Walker ER, Escoffery C. Results of a research study evaluating WebEase, an online epilepsy self-management program. *Epilepsy Behav* 2011; 22: 469-74.

27. Sajatovic M, Colon-Zimmermann K, Kahriman M, Fuentes-Casiano E, Liu H, Tatsuoka C, *et al.* A 6-month prospective randomized controlled trial of remotely delivered group format epilepsy self-management *versus* waitlist control for high-risk people with epilepsy. *Epilepsia* 2018; 59: 1684-95.

28. Sajatovic M, Tatsuoka C, Welter E, Perzynski AT, Colon-Zimmermann K, Van Doren JR, *et al.* Targeted self-management of epilepsy and mental illness for individuals with epilepsy and psychiatric comorbidity. *Epilepsy Behav* 2016; 64: 152-9.

29. Caller TA, Ferguson RJ, Roth RM, Secore KL, Alexandre FP, Zhao W, *et al.* A cognitive behavioral intervention (HOBS-COTCH) improves quality of life and attention in epilepsy. *Epilepsy Behav* 2016; 57: 111-7.

30. Brown DMY, Mahlberg N, Pohl D, Timmons BW, Bray SR, Streiner DL, *et al.* Can behavioral strategies increase physical activity and influence depressive symptoms and quality of life among children with epilepsy? Results of a randomized controlled trial. *Epilepsy Behav* 2019; 94: 158-66.

31. May TW, Pfafflin M. The efficacy of an educational treatment program for patients with epilepsy (MOSES): results of a controlled, randomized study. Modular Service Package Epilepsy. *Epilepsia* 2002; 43: 539-49.

32. Ridsdale L, McKinlay A, Wojewodka G, Robinson EJ, Mosweu I, Feehan SJ, *et al.* Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial. *Health Technol Assess* 2018; 22: 1-142.

33. Beretta S, Beghi E, Messina P, Gerardi F, Pescini F, La Licata A, *et al.* Comprehensive educational plan for patients with epilepsy and comorbidity (EDU-COM): a pragmatic randomised trial. *J Neurol Neurosurg Psychiatry* 2014; 85: 889-94.

34. Pfäfflin M, Schmitz B, May TW. Efficacy of the epilepsy nurse: results of a randomized controlled study. *Epilepsia* 2016; 57: 1190-8.

35. Rau J, May TW, Pfafflin M, Heubrock D, Petermann F. [Education of children with epilepsy and their parents by the modular education program epilepsy for families (FAMOSES)–results of an evaluation study]. *Rehabilitation* (*Stuttg*) 2006; 45: 27-39.

36. Jantzen S, Müller-Godeffroy E, Hallfahrt-Krisl T, Aksu F, Püst B, Kohl B, *et al*. FLIP&FLAP-a training programme for children and adolescents with epilepsy, and their parents. *Seizure* 2009; 18: 478-86.

37. Lua PL, Neni WS. A randomised controlled trial of an SMS-based mobile epilepsy education system. *J Telemed Telecare* 2013; 19: 23-8.

38. Edward KL, Cook M, Stephenson J, Giandinoto JA. The impact of brief lifestyle self-management education for the control of seizures. *Br J Nurs* 2019; 28: 348-54.

39. Turan Gürhopur FD, Işler Dalgiç A. The effect of a modular education program for children with epilepsy and their parents on disease management. *Epilepsy Behav* 2018; 78: 210-8.

40. Noble AJ, Marson AG, Blower SL. Psychological interventions for epilepsy: how good are trialists at assessing their implementation fidelity, what are the barriers, and what are journals doing to encourage it? A mixed methods study. *Epilepsy Behav* 2019; 97: 174-81.

41. Schroder J, Bruckner K, Fischer A, Lindenau M, Kother U, Vettorazzi E, *et al.* Efficacy of a psychological online intervention for depression in people with epilepsy: a randomized controlled trial. *Epilepsia* 2014; 55: 2069-76.

42. Borghs S, de la Loge C, Cramer JA. Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. *Epilepsy Behav* 2012; 23: 230-4.

43. Michaelis R, Tang V, Goldstein LH, Reuber M, LaFrance Jr WC, Lundgren T, *et al.* Psychological treatments for adults and children with epilepsy: Evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. *Epilepsia* 2018; 59: 1282-302.

44. Modi AC, Wagner J, Smith AW, Kellermann TS, Michaelis R. Implementation of psychological clinical trials in epilepsy: review and guide. *Epilepsy Behav* 2017; 74: 104-13.

TEST YOURSELF

(1) What are education-only interventions?

(2) What are skills-based psychological interventions?

(3) Skills-based psychological interventions improve HRQOL in adults and adolescents with epilepsy. What are the clinical implications?

Note: Reading the manuscript provides an answer to all questions. Correct answers may be accessed on the website, www.epilepticdisorders.com.